Fosamprenavir in Infants and Children with HIV-1 Infection
on April 27, 2012, the Food and Drug Administration (FDA) announced the extension of approval for fosamprenavir to include patients 4 weeks of age and older with HIV-1 infection. Fosamprenavir was approved by the FDA for use in adults on October 20, 2003 and has become a common part of highly active antiretroviral treatment (HAART) regimens. Approval was extended to children over 6 years of age in October 2007. With the availability of new clinical research resulting in the extension of approval to infants and young children, fosamprenavir is now an option for more patients with HIV-1 infection.
Abstract and Introduction
Introduction
on April 27, 2012, the Food and Drug Administration (FDA) announced the extension of approval for fosamprenavir to include patients 4 weeks of age and older with HIV-1 infection. Fosamprenavir was approved by the FDA for use in adults on October 20, 2003 and has become a common part of highly active antiretroviral treatment (HAART) regimens. Approval was extended to children over 6 years of age in October 2007. With the availability of new clinical research resulting in the extension of approval to infants and young children, fosamprenavir is now an option for more patients with HIV-1 infection.